The ResMed CDI (ASX: RMD) share price has been caught up in today’s market selloff.
In afternoon trade, the medical device company’s shares are down 4% to $33.58.
Is this a buying opportunity?
While today’s weakness in the ResMed share price is disappointing for shareholders, it could be a buying opportunity for the rest of us.
According to a recent note out of Morgans, its analysts have put an add rating and $40.80 price target on its shares.
Based on the current ResMed share price, this implies potential upside of 21% over the next 12 months.
Why is the broker bullish on the ResMed share price?
Morgans was pleased with the company’s performance during the first quarter and believes it will benefit in the short term from the recall of the rival Phillips device.
In respect to the recall, the broker previously commented: “We estimate the recall gain is c40% of Philips’ sleep device revenue (cUS$780m), or c13% of its market share (assuming it holds 33% share of a US$2.3bn market).”
However, it is the medium to long term that makes Morgans most positive on the ResMed share price. Its analysts are particularly positive on its connected-care digital platform and see major growth opportunities.
The broker explained: “While we believe the next few quarters will likely be volatile, as COVID-related demand for ventilators continues to slow and core sleep apnoea volumes gradually lift, nothing changes our medium/longer term view that the company remains well-placed as it builds a unique, patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.”
All in all, the broker appears to believe this could make it worth considering the sleep treatment focused medical device company’s shares as a buy and hold option.
The post Broker tips ResMed (ASX:RMD) share price to rise over 20% appeared first on The Motley Fool Australia.
Should you invest $1,000 in ResMed right now?
Before you consider ResMed, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and ResMed wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
More reading
- In the green: Here are the 5 best ASX healthcare shares of 2021
- 3 top ASX growth shares to buy in January
- Top brokers name 3 ASX shares to buy
- 2 excellent ASX growth shares offering big potential returns in 2022
- Why analysts love these ASX 200 blue chip shares
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/3EYDlM2
Leave a Reply